Human papillomavirus vaccination in HIV-infected women: Need for increased coverage

Expert Review of Vaccines

Volumn 15, Issue 1, 2016, Pages 105-117

  Kojic, Erna Milunka ^a   Rana, Aadia I ^a   Cu Uvin, Susan ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

HIV; HPV; immunogenicity; vaccination; women

Indexed keywords

WART VIRUS VACCINE;

CELLULAR IMMUNITY; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; MIXED INFECTION; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; REVIEW; UNITED STATES; VACCINATION; ADOLESCENT; ADULT; CHILD; COMPLICATION; DISEASE TRANSMISSION; IMMUNIZATION; IMMUNOLOGY; MALE; PAPILLOMAVIRUS INFECTIONS; PREVENTION AND CONTROL; UTILIZATION; YOUNG ADULT;

ADOLESCENT; ADULT; CHILD; DISEASE TRANSMISSION, INFECTIOUS; FEMALE; HIV INFECTIONS; HUMANS; IMMUNIZATION; MALE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; YOUNG ADULT;

EID: 84951568676     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2016.1110025     Document Type: Review

References (84)

1. Papers of special note have been highlighted as
2. ∗ of interest to readers
3. ∗ of considerable interest to readers
4. De Villiers EM. Cross-roads in the classification of papillomaviruses. Virology. 2013; 445 (1-2): 2-10.
5. Schiffman M, Castle PE. Human papillomavirus: epidemiology and public health. Arch Pathol Lab Med. 2003; 127 (8): 930-934.
6. Sexually transmitted diseases surveillance [Internet]. 2013 [cited 2015 Oct 4]. Available from: http://www.cdc.gov/std/stats13/other.htm#hpv
7. Dochez C, Bogers JJ, Verhelst R., et al. HPV vaccines to prevent cervical cancer and genital warts: an update. Vaccine. 2014; 32 (14): 1595-1601.
8. Clifford GM, Smith JS, Aguado T., et al. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer. 2003; 89 (1): 101-105.
9. Bosch FX, Burchell AN, Schiffman M., et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine. 2008; 26 Suppl 10: K1-16.
10. Bosch FX, Lorincz A, Munoz N., et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002; 55 (4): 244-265.
11. Bosch FX, Broker TR, Forman D., et al. Comprehensive control of human papillomavirus infections and related diseases. Vaccine. 2013; 31 Suppl 7: H1-31.
12. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 2006; 118 (12): 3030-3044.
13. Ahdieh L, Klein RS, Burk R., et al. Prevalence, incidence, and type-specific persistence of human papillomavirus in human immunodeficiency virus (HIV)-positive and HIV-negative women. J Infect Dis. 2001; 184 (6): 682-690.
14. Jamieson DJ, Duerr A, Burk R, et al., Group HIVERS. Characterization of genital human papillomavirus infection in women who have or who are at risk of having HIV infection. Am J Obstet Gynecol. 2002; 186 (1): 21-27.
15. Luque AE, Jabeen M, Messing S., et al. Prevalence of human papillomavirus genotypes and related abnormalities of cervical cytological results among HIV-1-infected women in Rochester, New York. J Infect Dis. 2006; 194 (4): 428-434.
16. Palefsky JM, Holly EA, Ralston ML., et al. Prevalence and risk factors for anal human papillomavirus infection in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women. J Infect Dis. 2001; 183 (3): 383-391.
17. Denny LA, Franceschi S, De Sanjose S., et al. Human papillomavirus, human immunodeficiency virus and immunosuppression. Vaccine. 2012; 30 Suppl 5: F168-174.
18. D'Souza G, Wiley DJ, Li X., et al. Incidence and epidemiology of anal cancer in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr. 2008; 48 (4): 491-499.
19. Patel P, Hanson DL, Sullivan PS., et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med. 2008; 148 (10): 728-736.
20. Silverberg MJ, Lau B, Justice AC., et al. Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis. 2012; 54 (7): 1026-1034.
21. Kojic EM, Cu-Uvin S, Conley L., et al. Human papillomavirus infection and cytologic abnormalities of the anus and cervix among HIV-infected women in the study to understand the natural history of HIV/AIDS in the era of effective therapy (the SUN study). Sex Transm Dis. 2011; 38 (4): 253-259.
22. Williams AB, Darragh TM, Vranizan K., et al. Anal and cervical human papillomavirus infection and risk of anal and cervical epithelial abnormalities in human immunodeficiency virus-infected women. Obstet Gynecol. 1994; 83 (2): 205-211.
23. Hessol NA, Holly EA, Efird JT., et al. Concomitant anal and cervical human papillomavirusV infections and intraepithelial neoplasia in HIV-infected and uninfected women. Aids. 2013; 27 (11): 1743-1751.
24. Strickler HD, Palefsky JM, Shah KV., et al. Human papillomavirus type 16 and immune status in human immunodeficiency virus-seropositive women. J Natl Cancer Inst. 2003; 95 (14): 1062-1071.
25. Madkan VK, Cook-Norris RH, Steadman MC., et al. The oncogenic potential of human papillomaviruses: a review on the role of host genetics and environmental cofactors. Br J Dermatol. 2007; 157 (2): 228-241.
26. Massad LS, Xie X, Burk RD., et al. Association of cervical precancer with human papillomavirus types other than 16 among HIV co-infected women. Am J Obstet Gynecol. Forthcoming 2015 Sep 30. pii: S0002-9378(15)01200-4. doi: 10.1016/j.ajog.2015.09.086.
27. Cobucci RN, Lima PH, De Souza PC., et al. Assessing the impact of HAART on the incidence of defining and non-defining AIDS cancers among patients with HIV/AIDS: a systematic review. J Infect Public Health. 2015; 8 (1): 1-10.
28. Engels EA, Biggar RJ, Hall HI., et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer. 2008; 123 (1): 187-194.
29. Massad LS, Seaberg EC, Watts DH., et al. Long-term incidence of cervical cancer in women with human immunodeficiency virus. Cancer. 2009; 115 (3): 524-530.
30. Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst. 2000; 92 (18): 1500-1510.
31. Viscidi RP, Kotloff KL, Clayman B., et al. Prevalence of antibodies to human papillomavirus (HPV) type 16 virus-like particles in relation to cervical HPV infection among college women. Clin Diagn Lab Immunol. 1997; 4 (2): 122-126.
32. Markowitz LE, Dunne EF, Saraiya M, et al., Centers for Disease C, Prevention, Advisory Committee on Immunization P. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007; 56 (RR-2): 1-24.
33. Centers for Disease C, Prevention. FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2010; 59 (20): 630-632.
34. Centers for Disease C, Prevention. Recommendations on the use of quadrivalent human papillomavirus vaccine in males-Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep. 2011; 60 (50): 1705-1708.
35. Monie A, Hung CF, Roden R., et al. Cervarix: a vaccine for the prevention of HPV 16, 18-associated cervical cancer. Biologics. 2008; 2 (1): 97-105.
36. Stanley M, Lowy DR, Frazer I. Chapter 12: prophylactic HPV vaccines: underlying mechanisms. Vaccine. 2006; 24 Suppl 3: S3/106-113.
37. Toft L, Storgaard M, Muller M., et al. Comparison of the immunogenicity and reactogenicity of Cervarix and Gardasil human papillomavirus vaccines in HIV-infected adults: a randomized, double-blind clinical trial. J Infect Dis. 2014; 209 (8): 1165-1173.
38. Toft L, Tolstrup M, Muller M., et al. Comparison of the immunogenicity of Cervarix(R) and Gardasil(R) human papillomavirus vaccines for oncogenic non-vaccine serotypes HPV-31, HPV-33, and HPV-45 in HIV-infected adults. Hum Vaccin Immunother. 2014; 10 (5): 1147-1154.
39. Herrero R, Gonzalez P, Markowitz LE. Present status of human papillomavirus vaccine development and implementation. Lancet Oncol. 2015; 16 (5): e206-e216.
40. Kreimer AR, Rodriguez AC, Hildesheim A., et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst. 2011; 103 (19): 1444-1451.
41. Dobson SR, McNeil S, Dionne M., et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. Jama. 2013; 309 (17): 1793-1802.
42. Group FIS. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007; 356 (19): 1915-1927.
43. Garland SM, Hernandez-Avila M, Wheeler CM., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007; 356 (19): 1928-1943.
44. Giuliano AR, Palefsky JM, Goldstone S., et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med. 2011; 364 (5): 401-411.
45. Palefsky JM, Giuliano AR, Goldstone S., et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med. 2011; 365 (17): 1576-1585.
46. Clark LR, Myers ER, Huh W., et al. Clinical trial experience with prophylactic human papillomavirus 6/11/16/18 vaccine in young black women. J Adolesc Health. 2013; 52 (3): 322-329.
47. Fife KH, Wu JW, Squires KE., et al. Prevalence and persistence of cervical human papillomavirus infection in HIV-positive women initiating highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2009; 51 (3): 274-282.
48. Kojic EM, Kang M, Cespedes MS., et al. Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women. Clin Infect Dis. 2014; 59 (1): 127-135.
49. Shire NJ, Welge JA, Sherman KE. Efficacy of inactivated hepatitis A vaccine in HIV-infected patients: a hierarchical bayesian meta-analysis. Vaccine. 2006; 24 (3): 272-279.
50. Weissman S, Feucht C, Moore BA. Response to hepatitis A vaccine in HIV-positive patients. J Viral Hepat. 2006; 13 (2): 81-86.
51. Rey D, Krantz V, Partisani M., et al. Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load. Vaccine. 2000; 18 (13): 1161-1165.
52. Overton ET, Sungkanuparph S, Powderly WG., et al. Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons. Clin Infect Dis. 2005; 41 (7): 1045-1048.
53. Weinberg A, Gona P, Nachman SA., et al. Antibody responses to hepatitis A virus vaccine in HIV-infected children with evidence of immunologic reconstitution while receiving highly active antiretroviral therapy. J Infect Dis. 2006; 193 (2): 302-311.
54. Levin MJ. Use of varicella vaccines to prevent herpes zoster in older individuals. Arch Virol Suppl. 2001; 17: 151-160.
55. Levin MJ, Song LY, Fenton T., et al. Shedding of live vaccine virus, comparative safety, and influenza-specific antibody responses after administration of live attenuated and inactivated trivalent influenza vaccines to HIV-infected children. Vaccine. 2008; 26 (33): 4210-4217.
56. Palefsky J, Poongulali S, Lensing SY., et al. AMC 054: safety and immunogenicity of the quadrivalent HPV vaccine in Indian HIV-infected women. Conference on retroviruses and opportunistic infections: 2014 March 3-6; Boston (MA). Abstract #855.
57. Giacomet V, Penagini F, Trabattoni D., et al. Safety and immunogenicity of a quadrivalent human papillomavirus vaccine in HIV-infected and HIV-negative adolescents and young adults. Vaccine. 2014; 32 (43): 5657-5661.
58. Denny L, Hendricks B, Gordon C., et al. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study. Vaccine. 2013; 31 (48): 5745-5753.
59. Kahn JA, Xu J, Kapogiannis BG., et al. Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV-infected young women. Clin Infect Dis. 2013; 57 (5): 735-744.
60. Levin MJ, Moscicki AB, Song LY., et al. Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old. J Acquir Immune Defic Syndr. 2010; 55 (2): 197-204.
61. Joura EA, Kjaer SK, Wheeler CM., et al. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine. 2008; 26 (52): 6844-6851.
62. Roberts C, Swoyer R, Bryan J. Evaluation of the HPV 18 antibody response in Gardasil(R) vaccinees after 48 mo using a pseudovirion neutralization assay. Hum Vaccin Immunother. 2012; 8 (4): 431-434.
63. Munoz N, Manalastas R Jr, Pitisuttithum P., et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet. 2009; 373 (9679): 1949-1957.
64. Block SL, Nolan T, Sattler C., et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics. 2006; 118 (5): 2135-2145.
65. Stokley S, Jeyarajah J, Yankey D, et al., Immunization Services Division NCfI, Respiratory Diseases CDC., et al. Human papillomavirus vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 2006-2014-United States. MMWR Morb Mortal Wkly Rep. 2014; 63 (29): 620-624.
66. CDC. Vaccines for children program (VFC). Atlanta (GA): Services UDOHaH, ed; 2014.
67. The affordable care act and vaccines [Internet]. 2015 [cited 2015 Oct 4]. Available from: http://www.hhs.gov/healthcare/facts/factsheets/2010/09/The-Affordable-Care-Act-and-Immunization.html
68. Centers for Disease C, Prevention. Human papillomavirus vaccination coverage among adolescent girls, 2007-2012, and postlicensure vaccine safety monitoring, 2006-2013-United States. MMWR Morb Mortal Wkly Rep. 2013; 62 (29): 591-595.
69. Elam-Evans LD, Yankey D, Jeyarajah J, et al., Immunization Services Division NCfI, Respiratory D, Centers for Disease C., et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years-United States, 2013. MMWR Morb Mortal Wkly Rep. 2014; 63 (29): 625-633.
70. Barroso LF 2nd. The role of human papilloma virus (HPV) vaccination in the prevention of anal cancer in individuals with human immunodeficiency virus-1 (HIV-1) infection. Ther Adv Vaccines. 2013; 1 (2): 81-92.
71. Hofstetter AM, Rosenthal SL. Factors impacting HPV vaccination: lessons for health care professionals. Expert Rev Vaccines. 2014; 13 (8): 1013-1026.
72. Women and HIV/AIDS in the United States [Internet]. 2015 [cited 2015 Oct 4]. Available from: http://kff.org/hivaids/fact-sheet/women-and-hivaids-in-the-united-states/
73. Castellsague X, Munoz N, Pitisuttithum P., et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. Br J Cancer. 2011; 105 (1): 28-37.
74. Human papillomavirus vaccines: WHO position paper, October 2014. Wkly Epidemiol Rec. 2014; 89 (43): 465-491.
75. Bowyer HL, Forster AS, Marlow LA., et al. Predicting human papillomavirus vaccination behaviour among adolescent girls in England: results from a prospective survey. J Fam Plann Reprod Health Care. 2014; 40 (1): 14-22.
76. Fiks AG, Grundmeier RW, Biggs LM., et al. Impact of clinical alerts within an electronic health record on routine childhood immunization in an urban pediatric population. Pediatrics. 2007; 120 (4): 707-714.
77. Tips and time-savers for talking with parents about HPV Vaccine [Internet]. 2015 [cited 2015 Oct 4]. Available from: www.cdc.gov/vaccines/who/teens/for-hcp-tipsheet-hpv.pdf
78. Masur H, Brooks JT, Benson CA, et al., National Institutes of H, Centers for Disease C, Prevention, America HIVMAotIDSo. Prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: updated guidelines from the Centers for Disease Control and Prevention, National Institutes of Health, and HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2014; 58 (9): 1308-1311.
79. Joura EA, Giuliano AR, Iversen OE., et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015; 372 (8): 711-723.
80. Schilling A, Parra M, Gutierrez M., et al. Coadministration of a 9-valent human papillomavirus vaccine with meningococcal and Tdap vaccines. Pediatrics. 2015 Sep;136(3):e563-e572. doi: 10.1542/peds.2014-4199. Epub 2015 Aug 3.
81. Smith JF, Brownlow M, Brown M., et al. Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions. Hum Vaccin. 2007; 3 (4): 109-115.
82. EMA [Internet]. 2014 [cited 2015 Oct 4]. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Summary-for-the-public/human/000721/WC500024634.pdf.
83. Comparetto C, Paty-Billiaux, Rousset A., et al. Two doses of vaccin in profilactc vaccination against HPV infection: a new option. 29th annual international papillomavirus conference and public health and clinical workshops; 2014 August 21-25; Seattle, WA. Abstract # PH.PP06.04.
84. Kjaer SK, Blomberg M, Munk C., et al. Effect of number of HPV vaccination doses on genital wart incidence-a nationwide study of 550,000 young girls. 29th annual international papillomavirus conference and public health and clinical workshops; 2014 August 21-25; Seattle, WA. Abstract # PH.OA02.03.